1.1 High-Flow Oxygen

1.1.1 Evidence base

The landmark RCT

peer-reviewed Cohen AS, Burns B, Goadsby PJ. “High-flow oxygen for treatment of cluster headache: a randomized trial.” JAMA. 2009;302(22):2451–7. Double-blind randomised placebo-controlled crossover trial at the National Hospital for Neurology and Neurosurgery, London, 2002–2007. 109 enrolled, 76 analysed (57 episodic, 19 chronic). Each participant treated four attacks — two with 100% oxygen at 12 L/min via face mask for 15 minutes, two with high-flow air (JAMA 2009; PMID 19996400, DOI 10.1001/jama.2009.1855, ISRCTN94092997).

Outcome at 15 min	Oxygen	Air
Pain-free or adequate relief	78% (95% CI 71–85; 150 attacks)	20% (95% CI 14–26; 148 attacks)

Wald χ²(5) = 66.7, P < .001. No important adverse events. This single trial is the backbone of every “Level A / strong recommendation” for oxygen worldwide, and its 78% number is the one you will see repeated in German, Japanese and Australian sources alike.

Earlier trials

peer-reviewed Kudrow L, Headache 1981;21(1):1–4 — the first systematic study. 7 L/min for 15 minutes aborted more than 7 of 10 attacks in 82% of patients, compared with 70% for sublingual ergotamine. Kudrow also noted a rebound effect in some oxygen users (Guo et al., Med Gas Res 2019, PMC7802413). The Japanese Headache Society records Kudrow’s timing detail: improvement within 7 minutes in 62%, with a further 31% improving at 8–10 minutes (JHS CQ1) — non-English source, Japanese.

peer-reviewed Fogan L, Arch Neurol 1985;42(5):362–3 — double-blind oxygen vs room air, 6 L/min for 15 min, N=19 men aged 20–50. Relief score (0=none to 3=complete relief) 1.93 ± 0.22 for oxygen vs 0.77 ± 0.23 for air, F test P<.01 (JHS CQ1, Japanese source). Described elsewhere as 56% of oxygen users getting relief in more than 80% of attacks vs 7% on air (Guo et al. 2019).

peer-reviewed Igarashi et al. 1988 (五十嵐ら, Nihon Naika Gakkai Zasshi 77(2):267) — open-label, N=23, oxygen 7 L/min via face mask side port. 17 patients improved, mean onset of improvement 3.1 ± 3.1 min, pain resolution at 13.5 ± 6.2 min (JHS CQ1). Non-English source, Japanese — this trial is essentially invisible in the Anglophone literature and is part of why Japan’s guideline settled on 7 L/min.

Cochrane

peer-reviewed Bennett MH, French C, Schnabel A, Wasiak J, Kranke P, Weibel S. “Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache.” Cochrane Database Syst Rev. 2015;(12):CD005219 (PMC8720466, DOI 10.1002/14651858.CD005219.pub3, PMID 26709672). 11 trials, 209 participants in the abstract analysis. For cluster headache: normobaric oxygen — 3 trials, 145 participants; hyperbaric oxygen — 2 trials, 29 participants.

For hyperbaric oxygen in CH the pooled result was RR 11.38 (95% CI 0.77–167.85, P=0.08), single trial, no evidence of effectiveness — the enormous confidence interval reflects that Di Sabato 1993 had n=13 and produced complete resolution within 20 minutes in 6/7 (86%) HBOT vs 0/6 sham, sustained at ≥48 h in 86% vs 0%. Trial quality across the review was rated “poor to moderate.” The review was declared stable in 2016 and has not been updated.

Read this honestly: Cochrane’s verdict is that normobaric oxygen has real supporting evidence (driven by Cohen 2009), while hyperbaric oxygen is unproven — the studies are tiny, the point estimate is dramatic, and the confidence interval spans “no effect” to “miraculous.” Do not let the 86% figure travel without its n=13.

The flow-rate trial that complicated things

peer-reviewed Dirkx THT, Haane DYP, Koehler PJ. “Oxygen treatment for cluster headache attacks at different flow rates: a double-blind, randomized, crossover study.” J Headache Pain. 2018;19(1):94 (PMC6755552, DOI 10.1186/s10194-018-0917-4, PMID 30306284). 98 enrolled at 28 Dutch centres (target 110), 70 valid, 56 used both flow rates, 604 attacks analysed. Salter Labs E-8140 non-rebreather mask. 7 L/min vs 12 L/min.

Outcome	7 L/min	12 L/min	p
Pain-free, first 2 days (median %)	0% (IQR 0–37.5)	0% (IQR 0–83.5)	0.180
VAS drop (median)	4.09	4.33	0.243
Successfully treated attacks (median %)	92.86%	—	—

Exploratory analysis gave OR 0.73 (95% CI 0.52–1.02, p=0.061) for pain-freedom at 12 vs 7 L/min — i.e. numerically favouring the lower flow rate, and on one measure more patients were pain-free at 7 L/min (p=0.039). Yet patients preferred 12 L/min. Critically, the primary endpoint rested on only 5 patients and 27 attacks, so this trial is badly underpowered for its own primary question.

This is a genuine, unresolved conflict. The EAN guideline cites a flow-comparison odds ratio of 3.75 (95% CI 0.58–24.28) favouring 12 L/min (EAN 2023) — a point estimate in the opposite direction from Dirkx, with a confidence interval so wide it means almost nothing. Honest summary: nobody has convincingly established the optimal flow rate. The community consensus (≥15 L/min) is not evidence-based in the trial sense; neither is Japan’s 7 L/min. What is established is that 12 L/min via a proper mask beats air.

Demand-valve and mask-comparison studies

peer-reviewed Petersen AS, Barloese MCJ, Lund NLT, Jensen RH. “Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study.” Cephalalgia — Danish Headache Center, Rigshospitalet. 57 CH patients, 102 attacks, inpatient single-blinded semi-randomised placebo-controlled crossover, comparing demand-valve oxygen (DVO) vs O2ptimask vs simple mask at 15 L/min (Cephalalgia PDF). O2ptimask and DVO decreased the need for rescue medication compared with the simple mask. However, the EAN guideline’s reading is that no statistically significant effect was demonstrated between groups (EAN 2023) — flagging this as a contested interpretation. Danish source — the Danish Headache Center is the main non-Anglophone group doing oxygen delivery research.

peer-reviewed A demand-valve pilot published in Pain Medicine 2013;14(4):455–9 (DOI 10.1111/pme.12055, PMID 23369112, NCT01298921) had only 4 participants — worth knowing so that community claims of “trial-proven demand valves” can be sized correctly. Review: Oude Nijhuis, Haane, Koehler, Cephalalgia 2016, DOI 10.1177/0333102415616878.

1.1.2 Mechanism of action

Genuinely unsettled. Candidate mechanisms:

peer-reviewed Cerebral vasoconstriction; attenuation of neurogenic inflammation; attenuation of parasympathetic overactivity — the three mechanisms listed by the Japanese Headache Society, which states plainly that the mechanism “is still not clear in many respects” (「いまだ明確でない点が多い」) (JHS CQ1). Japanese source.

peer-reviewed Akerman/Goadsby preclinical work: oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of the trigeminal-autonomic reflex, but not during direct dural activation — implying oxygen acts on the parasympathetic/facial nerve limb rather than on trigeminal nociception directly (King’s College London research portal). This is the most mechanistically satisfying explanation currently on offer, and it predicts that oxygen should work better the earlier in the attack it is given — which matches patient experience.

peer-reviewed The Australian Prescriber review lists: “vasoconstriction; blocks the trigeminal autonomic reflex; inhibits protein release and activity in the superior salivatory nucleus” (Ray, Stark, Hutton, Aust Prescr 2022;45:15–20, DOI 10.18773/austprescr.2022.004).

community report OUCH-UK’s patient-facing leaflet offers a different and almost certainly wrong mechanism: “the hypothalamus… sends out a false message that the brain is short of oxygen [evidenced by yawning] and the blood vessels immediately start expanding in the search for O2; this puts enormous pressure on the nerves inside the skull” (OUCH-UK, Oxygen for CH 2023). Flagged as a folk mechanism. The vascular-pressure model of headache pain was abandoned by researchers decades ago. It does no harm to patients — the practical advice attached to it is sound — but it should not be cited as science.

1.1.3 Delivery technique — what the numbers actually mean

peer-reviewed Mo H, Chung SJ, Rozen TD, Cho S-J. “Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders.” J Clin Neurol. 2022;18(3):271–279 (PMC9163947, DOI 10.3988/jcn.2022.18.3.271) gives the delivery-device table that explains most of the confusion in this field:

Device	Flow rate	Delivered FiO₂
Nasal cannula	1–6 L/min	0.24–0.44
Simple face mask	5–12 L/min	0.20–0.50
Non-rebreather / reservoir mask	10–15 L/min	0.55–0.95
Demand-valve oxygen (DVO)	40–160 L/min	0.40–1.00
Venturi mask	40–50 L/min	variable
High-flow nasal cannula	40–60 L/min	variable

The key insight buried in that table: a non-rebreather at 12–15 L/min does not deliver 100% oxygen. Mo et al. explicitly classify 6–15 L/min via NRM as intermediate flow, not true high flow. The reason is peak inspiratory flow: an adult breathing hard during a cluster attack can inhale at 30–60 L/min. A 15 L/min supply cannot keep up, the reservoir bag collapses, and room air is entrained around the mask seal. A demand valve solves this by delivering gas as fast as you can pull it, shutting off on exhalation and delivering undiluted 100% oxygen.

This single physiological fact reconciles most of the guideline-vs-community disagreement below. The community is not being irrational when it pushes for higher flow rates; it is trying to defeat dilution.

Guideline-recommended technique

Source	Flow	Duration	Mask	Position
EAN 2023 (Europe) peer-reviewed	100% O₂ at ≥12 L/min, “in some cases up to 15 L/min”	15 min (detailed section says 20 min)	Non-rebreather required; “nasal cannulae are not sufficient”	not specified
Japanese Headache Society 2018 peer-reviewed	>90% O₂ at 7 L/min via face mask side port	15 min	face mask	not specified
DMKG (Germany) peer-reviewed/community report	7–15 L/min	15–20 min	High-concentration (non-rebreather) mask; nasal cannula “usually not sufficient”	sitting, leaning forward; do not hyperventilate
Australian Prescriber 2022 peer-reviewed	7–12 L/min	15 min	non-rebreather, from a cylinder	not specified
Exeter Headache Clinic (UK NHS) community report	Start 15 L/min, then reduce to 6–8 L/min — enough to keep the reservoir bag inflated	until pain gone +5 min to “mop up”	reservoir-bag mask	not specified

Sources: EAN 2023; JHS CQ1; DMKG “Sauerstoffbehandlung bei Cluster-Kopfschmerz”; Australian Prescriber; Exeter Headache Clinic 2021/2023.

The German guidance is the most complete patient-facing protocol in any language, and it is the only official document that specifies both body position and a warning against hyperventilating. Verbatim, from the DMKG:

„Sauerstoffflasche, kein Sauerstoffkonzentrator.” (Oxygen cylinder, not an oxygen concentrator.) „Sofort bei Beginn der Attacke mit der Sauerstofftherapie beginnen.” (Start immediately at attack onset.) „Inhalation in sitzender, vornüber gebeugter Position.” (Inhale sitting, leaning forward.) „Nicht hyperventilieren (übermäßiges Atmen).” (Do not hyperventilate.) „Verwendung einer Hochkonzentrationsmaske (Non-Rebreather Maske)… eine sogenannte Nasensonde oder Nasenbrille ist meist nicht ausreichend.”

German source. Note the direct conflict with clusterinfo.org’s community protocol below, which instructs demand-valve users to hyperventilate deliberately.

Timing

peer-reviewed/community report Every source agrees on this and it is probably the highest-yield practical point in the whole chapter: start at the first hint of the attack, before pain is established. OUCH Belgium’s patient leaflet is explicit that treatment should begin at the first symptom, before pain (OUCH Belgium oxygen leaflet) — Belgian/French source. Exeter: “As soon as you know an attack is starting” (Exeter). DMKG: „Sofort bei Beginn der Attacke.”

For someone with chronic daily CH this has an operational consequence: the cylinder needs to be within arm’s reach of where you sleep and where you work, not in a cupboard. Access latency is part of efficacy.

The “mop up” question

community report Both Exeter Headache Clinic and OUCH-UK’s forum advise staying on oxygen after the pain has stopped — Exeter says 5 minutes, “to ‘mop up’ the attack and prevent possible rebound, which some patients find is a problem”; the OUCH-UK forum consensus is 5–10 minutes at 15 L/min (Exeter; OUCH-UK forum, oxygen use).

No trial has tested this. It rests entirely on the rebound phenomenon Kudrow described in 1981 historical and on accumulated patient experience. It costs nothing and is plausible; label it as practice wisdom, not evidence.

1.1.4 Community-optimised technique — where the community diverges from the guidelines

This is the most interesting divergence in the acute-treatment literature, because the community is arguably ahead of the guidelines on delivery and behind them on mechanism.

Flow rate

community report Clusterbusters (US) recommends prescriptions be written for a minimum of 12–15 LPM, and its advocacy page states patients need “a non-rebreather mask (no holes near the nose), a flow rate of at least 15 lpm, and to use one of two breathing techniques for 15–20 minutes” (Clusterbusters CMS coverage page; Clusterbusters oxygen knowledgebase).

community report clusterinfo.org goes considerably further: “25 LPM or more is recommended”; “At least 25 LPM is strongly recommended”; and “Regulators delivering 40 LPM are often available and inexpensive — at that flow the setup can abort attacks about as quickly as a demand valve,” at the cost of using more oxygen per attack (clusterinfo.org oxygen guide).

Divergence, stated plainly: guidelines say 7–15 L/min. Clusterbusters says ≥15. clusterinfo says ≥25, ideally 40. There is no trial evidence at 25 or 40 L/min via non-rebreather. The physiological rationale (matching peak inspiratory flow, preventing reservoir-bag collapse and room-air entrainment) is sound and is supported by the Mo et al. FiO₂ table above peer-reviewed, but the specific numbers are extrapolation, not data. The one trial that directly compared flow rates found no benefit of 12 over 7 L/min, and hinted at the reverse peer-reviewed (Dirkx 2018).

My honest read: the community position is more likely right than wrong on physiological grounds, but it is currently a hypothesis wearing the clothes of a consensus. If you are going to try higher flow, the reservoir bag is your instrument — turn it up until the bag no longer collapses on your deepest inhale, and no further.

Breathing technique

community report clusterinfo.org describes two distinct techniques (clusterinfo.org):

• Demand valve: “Hyperventilate on pure oxygen: full inhale, full exhale, repeat as fast as possible.” Described as “widely considered the fastest and easiest way to abort a cluster attack with oxygen.”
• Non-rebreather / reservoir bag: “Forceful deep breathing: empty your lungs, then take a deep breath of pure oxygen. Repeat as fast as your reservoir bag can keep up. Only pause between breaths if the bag hasn’t refilled.”

community report Clusterbusters describes “one of two breathing techniques” but does not name them on the CMS page (Clusterbusters). Its provider-facing prescription wording, authored with Dr Stewart Tepper (2017), specifies: “Sit up and lean forward and breathe deeply 10–15 L/minute for up to 20 minutes per attack” (Clusterbusters provider guide).

community report A minority technique from r/clusterheads uses reverse diaphragmatic / Ujjayi-style breathing as an abortive (r/clusterheads thread). Single-patient anecdote. Included for completeness, not endorsed.

Direct conflict to be aware of: the German DMKG explicitly warns against hyperventilation peer-reviewed; clusterinfo.org explicitly instructs hyperventilation with a demand valve community report. These are not fully reconcilable. The plausible resolution is that hyperventilating on room-air-diluted gas causes hypocapnia and cerebral vasoconstriction with little benefit and some risk of dizziness/tetany, whereas hyperventilating on genuinely 100% oxygen from a demand valve may accelerate the therapeutic effect. This is my inference, not a documented finding. Treat as unresolved.

Non-rebreather vs demand valve

community report clusterinfo.org’s comparison (source):

	Demand valve	Non-rebreather + high-flow regulator
Speed	“the quickest way to abort an attack with oxygen”	slower unless flow is very high
Prescribing	“can be harder to get prescribed”	“often easier to get prescribed”
Cost	“Demand valves themselves are expensive”	40 LPM regulators “often available and inexpensive”

Explicitly ruled out by the same guide: nasal cannulas; masks with open side vents; simple face masks without a reservoir bag; oxygen concentrators (“They produce oxygen at lower purity and at a flow rate too low for cluster aborts”). Practical hack given: “If your prescribed non-rebreather mask has side vents, you can block them.”

community report OUCH-UK distinguishes “standard high flow oxygen [Short Burst Oxygen Therapy]” from “ultra high flow oxygen, delivered via a device known as a demand valve… similar to the device used for entonox in childbirth” (OUCH-UK 2023).

peer-reviewed The trial evidence behind the demand-valve preference is thin: one 4-participant pilot (Pain Med 2013) and the Danish mask-comparison trial where DVO reduced rescue medication use but did not reach significance between groups on the EAN’s reading (Petersen et al.; EAN 2023). clusterinfo.org’s summary — “demand valves roughly halved the need for rescue medication compared with a standard mask, and most patients preferred them” — is a fair reading of the Danish data but omits the significance caveat community report.

The welding-oxygen route

community report Both Clusterbusters and clusterinfo.org document patients bypassing the medical system entirely and buying oxygen and regulators from welding suppliers — clusterinfo.org calls it “Welding oxygen: a cheaper, prescription-free route”; Clusterbusters says that because Medicare/Medicaid patients must pay out of pocket, “many people resort to using welding oxygen” (clusterinfo.org; Clusterbusters provider guide).

Stated without endorsement. Welding-grade oxygen is chemically the same gas but is not manufactured, handled or documented to pharmaceutical standards, and the practice sits outside any regulatory framework. Its prevalence is itself the strongest available indictment of oxygen access policy — people in this much pain do not improvise with compressed-gas cylinders for fun.

1.1.5 Citizen-science efficacy data

citizen science Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. “Survey Analysis of the Use, Effectiveness, and Patient-Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache.” Headache. 2018;58(10):1568–1578 (PMID 30221765, DOI 10.1111/head.13405). Secondary analysis of the Clusterbusters® Medication Use survey, funded by Clusterbusters, analysed at Yale/VA Connecticut. N=493 adults with validated CH diagnosis. This is the single best example of citizen science and academic medicine collaborating in this disease.

Finding	Result
Oxygen efficacy at flow rates >10 L/min	81.5%
Injectable sumatriptan efficacy in the same group	80.5%
Difference	Did not differ significantly in any group examined
Flow rate >10 L/min as predictor of oxygen response	OR 2.36, P=.016
Male gender as predictor of oxygen response	OR 2.07, P=.031
Current or historical cigarette smoking as predictor	OR 2.25, P=.017
Predictors of sumatriptan response	None identified

Most commonly used delivery system: non-rebreather-type mask. The authors conclude that oxygen at sufficiently high flow has efficacy comparable to injectable sumatriptan, and note that “most comments about side effects and concerns were directed at triptans.”

Two odd findings worth flagging. First, smoking history predicts better oxygen response — the authors say the reason “requires further exploration.” Second, male gender predicts better response. Neither has a satisfying explanation. The smoking association recurs independently below.

peer-reviewed Backx et al. 2010, summarised in Guo et al. 2019: shorter attacks and absence of interictal pain were positively associated with oxygen response; photophobia/phonophobia, nausea/vomiting and restlessness were negatively associated. Three predictors of poor response: no past history of smoking; interictal headache; longest attack period >180 min.

Unexplained correlation, flagged: two independent datasets — one clinical, one community-survey — both find that never having smoked predicts a worse oxygen response. This is counterintuitive (oxygen is contraindicated in active smokers for fire-safety and respiratory reasons) and has no accepted mechanistic explanation. It may be a marker for a distinct CH phenotype rather than a causal effect of smoking. Unknown.

citizen science Pearson et al. 2019, Cluster Headache Questionnaire, n≈3251 (subjective oxygen efficacy): complete remission 13%, very effective 41%, moderately effective 27%, minimally effective 12%, completely ineffective 7% (reported in Guo et al. 2019). The full PubMed record (PMID 30632614) returned an NCBI access block during research and could not be independently verified — treat the exact percentages as second-hand.

peer-reviewed Aggregated survey data: subjective efficacy rated complete or very effective in 29–54% of patients; time to complete pain relief ≤20 min in 51%, but >40 min in 27% (Mo et al. 2022).

peer-reviewed Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M. “Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey Studies.” Curr Pain Headache Rep. 2022;26(8):623–637 (PMC9436841, DOI 10.1007/s11916-022-01063-5, PMID 35759175). University of Eastern Finland / Yale / Helsinki. 994 articles screened, 9 surveys, 5419 respondents, 2000–2020. Finnish-led — note the search used English-language terms only, so non-Anglophone surveys were structurally excluded.

Findings directly relevant here:

• Oxygen and subcutaneous triptan injections were the two most-reported-effective abortive treatments.
• Injectable sumatriptan was consistently reported as more effective than oral or nasal triptans.
• Oxygen was “the clinically most effective conventional abortive treatment and… most reported as efficacious in all reviewed studies.”
• Statistically significant episodic-vs-chronic differences were found only for oxygen and triptans — both considered more effective in episodic than in chronic CH. This matters enormously for a chronic daily sufferer and is repeated in the triptan section below.
• Overall: “There were no results disagreeing with the current knowledge” — i.e. for the acute treatments, community self-report and trial data broadly agree.

Respondent characteristics across the nine surveys: male:female 2.03–3.82; mean/median ages 40–50 in seven of nine studies; 53.8–77% current or former smokers; CCH/ECH ratios ~0.18–1.16.

1.1.6 Access barriers by country

This is where oxygen stops being a medical question and becomes an administrative one. peer-reviewed Mo et al. note that a 2017 survey found oxygen and its delivery devices are not uniformly covered anywhere in the world (Mo et al. 2022).

Australia

peer-reviewed Oxygen “may be ordered from medical gas supply companies with a prescription” (Ray, Stark & Hutton, Australian Prescriber 2022;45:15–20). The same review states that drugs used for acute and preventive CH treatment in Australia are off label though evidence-supported, that choice of acute therapy depends on patient factors and cost, and that intranasal zolmitriptan is not available in Australia. Contraindications listed for oxygen: active smokers; type 2 respiratory failure.

Assessment: Australia has no PBS pathway for cluster-headache oxygen; supply is a private arrangement with a medical gas company (BOC, Air Liquide, Supagas and similar) on a doctor’s prescription, and the cost falls on the patient. There is no national home-oxygen scheme for CH equivalent to the UK’s HOOF. State-based domiciliary oxygen programmes exist but are written around chronic hypoxaemic respiratory disease, which CH patients by definition do not have. I could not locate an Australian government document that explicitly addresses cluster-headache oxygen funding — treat the absence of a scheme as likely but not formally verified.

Practical implication for a chronic Australian patient: you are looking at private cylinder rental plus refills, indefinitely, with no rebate. Ask specifically for a large static cylinder plus a small portable one, a regulator that goes to at least 15 L/min (higher if you can get it), and non-rebreather masks — and expect to specify all of it yourself, because the supplier’s default assumption will be a 2–4 L/min respiratory patient.

United Kingdom

community report OUCH-UK gives the most operationally detailed access guidance of any patient organisation in any country (OUCH-UK, Oxygen for CH 2023):

England and Wales:

• Patient downloads the Home Oxygen Order Form (HOOF) from OUCH’s website — “part completed ready for a cluster headache sufferer.”
• GP must also complete the Home Oxygen Consent Form (HOC) and the Individual Home Oxygen Risk Management Form (IHORM), both available at the surgery.
• GP submits the HOOF online via the oxygen company’s portal, entering flow rate, cylinder type and mask.
• “If the GP has not signed the HOOF form to say he has completed the risk management form, the oxygen supply company will reject the HOOF form.”
• “If you smoke, or anyone in your house smokes, then oxygen will not be supplied.”
• The supplier contacts the patient directly; the delivery engineer demonstrates use and supplies masks “as well as a spare cylinder upon request.”
• Demand-valve oxygen has its own HOOF form, also pre-completed by OUCH, and “at present demand valve oxygen therapy is only available in England and Wales.”

The single most useful piece of advocacy intelligence in this entire chapter community report:

“Some GPs may say they can’t prescribe the oxygen and that it has to be prescribed by a secondary clinician [i.e., a consultant]. This is not so, as it is specifically laid down in the Home Oxygen Assessment Service (HOAS) specification that GPs can prescribe oxygen for CH sufferers for pain relief. There is a copy of the HOAS specification in every doctor’s surgery.”

Scotland and Northern Ireland: “oxygen can only be prescribed by a secondary clinician, i.e. a consultant, so it is more important than ever that you seek a referral to a headache specialist.”

community report OUCH-UK’s clinician-facing sheet states 100% oxygen at 12 L/min for up to 15 min and describes CH as “the only evidence-based use for short-burst oxygen therapy in patients who do not have hypoxaemia” (OUCH-UK GP/neurologist information). NHS England London published borough-level cluster headache oxygen guidance in September 2021 (NHS England London).

community report Fire-safety framing from Exeter Headache Clinic: “Two out of every three fires where there is home oxygen are the result of the user smoking” and “one in four people where the fire is a result of smoking while using oxygen die from their injuries. Vaping is also a significant risk” (Exeter). Given that CH populations are 54–77% current or former smokers citizen science, this exclusion criterion removes oxygen from a large fraction of the people who most need it — a structural cruelty in the system that is rarely discussed.

United States

peer-reviewed Inhaled oxygen for CH is not FDA-approved; injectable sumatriptan is “the only FDA-approved pharmacologic intervention for cluster headache” (Schindler et al. 2018). The same paper: “Current restrictions on access to inhaled oxygen, which exist at many levels, limit the therapeutic options available for patients with cluster headache… [and] do a disservice to this patient population and the providers who deliver their care.”

community report Concrete US cost figures, from Clusterbusters (provider guide):

• “Centers for Medicaid and Medicare Services (CMS) continue to deny coverage for home oxygen for cluster headache.”
• Commercial insurance often does cover it (Cigna is named as listing it), though “your commercial insurance may try to deny coverage and request more information.”
• “Cluster patients who have Medicaid or Medicare will have to pay out of pocket, which can be less than $1,000 per year for episodics, but could exceed $5,000 a year for chronics.”
• Billing codes given: HCPCS E0424, E0441, E0443; ICD-10 G44.009 / G44.019 / G44.029 / G44.011 / G44.021 / G44.001.

community report The CMS advocacy arc: the original National Coverage Determination denied home oxygen for CH (CMS decision memo); a Proposed Decision Memo issued 2 July 2021 signalled benefit for “selected individuals,” with a comment deadline of 31 July 2021, 5pm ET (Clusterbusters; CMS public comments).

Clusterbusters’ objections to the proposed wording are worth recording because they are a case study in how coverage language becomes a clinical barrier:

• The word “selected” would make neurologists hesitate, “because they might not know whether a patient qualifies to try it.” Clusterbusters’ position: “every clusterhead needs to try high-flow oxygen, not a ‘selected’ few.”
• The proposal left determination to the four Medicare Administrative Contractors via Local Coverage Determination policies, meaning “a person with Medicare in one U.S. region could receive oxygen while Medicare might deny oxygen to someone in another region.” Clusterbusters demanded a National Determination.
• The proposal contemplated requiring patients to demonstrate that oxygen aborts their attacks, in an ED or physician’s office, during an attack. Clusterbusters’ objection: attacks come on fast and destroy concentration; driving anywhere during one is unreasonable; the venue “would likely not have the oxygen setup needed to try the treatment correctly,” and incorrect administration could produce a false negative that then disqualifies the patient from home oxygen.

Related advocacy: Alliance for Patient Access; US Pain Foundation, “The Never-Ending Battle for Oxygen Coverage”.

Status caveat: Clusterbusters’ page headline states CMS “will soon cover” oxygen for select patients, but the page is undated and describes a proposed memo from 2021. Whether a final national determination has been issued, and in what form, is not established by the sources gathered here — treat as unresolved.

Germany / EU

peer-reviewed/community report Germany has the cleanest reimbursement pathway found in any country (DMKG):

• „Die Kosten für die Sauerstoffbehandlung werden von den gesetzlichen Krankenkassen übernommen, dazu ist eine ärztliche Verordnung erforderlich.” — Costs are covered by the statutory health insurers; a medical prescription is required.
• The BfArM approved, on 14 December 2007, “Sauerstoff, 100% Gas zur medizinischen Anwendung, druckverdichtet (Druckgasflaschen)” specifically for the indication “Behandlung von Cluster-Kopfschmerz in Deutschland” — approval number 69557.00.00. Germany formally licensed oxygen as a medicine for cluster headache. Almost nowhere else has.
• The statutory insurers’ aids catalogue (Hilfsmittelkatalog) lists “Druckminderer für Druckgasflaschen” for the indication cluster headache under position number 14.24.05.0.

The DMKG even publishes a model prescription — a template a patient can hand to a GP:

Standard supply	Spec
1 × pressure regulator	range 0–15 L/min, Hilfsmittel position 14.24.05.0
2 × cylinder	10 litre, medical oxygen, 200 bar, product type 14.99.99.1
2 × non-rebreather inhalation mask	—

Additional, for mobile use	Spec
1 × pressure regulator	range 0–15 L/min
2 × cylinder	2 litre, medical oxygen, 200 bar
1 × carry bag for cylinder	—
1 × non-rebreather inhalation mask	—

DMKG also advises contacting the insurer’s aids department immediately on diagnosis and faxing the prescription through. German source. The 10 L / 2 L cylinder split is the most concrete portability guidance found anywhere and is worth copying regardless of country: one large static cylinder, one 2-litre portable with a bag. Further German guidance: DMKG 2016 cluster guideline; DGN guideline.

Japan

peer-reviewed Home oxygen therapy (HOT) for cluster headache became reimbursable under Japanese national health insurance in the April 2018 fee revision (「2018年度の診療報酬改訂で群発頭痛患者における在宅酸素療法（home oxygen therapy: HOT）の保険適用が認められるようになり」). Prior to that, HOT reimbursement was restricted to severe chronic respiratory failure (COPD, post-TB sequelae, interstitial pneumonia, lung cancer), pulmonary hypertension and chronic heart failure. The new criterion is narrow and precise: patients diagnosed with cluster headache who are in a cluster period and have at least one headache attack per day on average (「群発期間中の患者であって，１日平均１回以上の頭痛発作を認めるもの」) (JHS CQ1). See also MHLW documentation and the Japanese Neurology Society 2021 headache guideline. Japanese sources.

Two further Japanese details that do not appear in English-language reviews:

• Oxygen concentrators capable of ≥90% concentration at ≥7 L/min have been confirmed as equivalent in usefulness to cylinder oxygen (「90％以上の濃度で７L/分以上の酸素供給が可能な装置では，酸素ボンベによる酸素吸入と同様の有用性が確認されている」), citing Yamada 2017, Kōchi-ken Ishikai Igaku Zasshi 22(1):214–219. This directly contradicts the German and community position that concentrators are useless. The reconciliation is that Japan’s target flow is 7 L/min, which a high-capacity concentrator can meet, whereas 15–40 L/min it cannot. If you are running a low-flow protocol, a concentrator may be viable; if you are running the community high-flow protocol, it is not.
• “Spray-can oxygen is ineffective because the concentration is insufficient” (「スプレー缶式の酸素吸入では濃度が不足するため効果がない」) — a useful explicit debunking of the canned-oxygen products sold in Japanese convenience stores.

Japan explicitly frames oxygen as the answer to the triptan dose-limit problem. The guideline states that oxygen is expected to help patients with sumatriptan contraindications or side effects, and those “with frequent attacks for whom the insurance-approved sumatriptan kit limit of twice daily made adequate treatment difficult,” noting that oxygen inhalation “can be used many times a day” (「1日に何度も使用可能」). This is the clearest official articulation anywhere of the logic that matters most to a chronic daily sufferer.

Denmark

peer-reviewed/community report The Danish Headache Center at Rigshospitalet is the principal non-Anglophone research group on oxygen delivery hardware (see Petersen et al. mask-comparison trial above). Danish patient- and clinician-facing material: Sundhed.dk patient handbook, klyngehovedpine; Ugeskrift for Læger review; DHOS Referenceprogram 2010. Danish sources.

1.1.7 Oxygen — bottom line for a chronic daily sufferer

Advantages that matter specifically in chronic CH: peer-reviewed EAN states oxygen “can be used several times per day,” has “no contraindications” and “no interactions,” and has a low adverse-event profile (EAN 2023). In a disease where the best drug has a hard ceiling of two doses per day, the treatment with no ceiling is structurally the most important one you have, even if its per-attack efficacy were slightly lower.

The honest caveat: peer-reviewed the systematic review of survey studies found oxygen is significantly less effective in chronic than in episodic CH (Rusanen et al. 2022). Cohen 2009 included only 19 chronic patients out of 76 and did not report a chronic-specific response rate. The 78% figure should not be assumed to apply to chronic CH.